DAWN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Day One Biopharmaceuticals Inc (DAWN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong revenue growth, a solid cash position, and positive future prospects driven by its OJEMDA product. Despite short-term technical weakness, the long-term growth potential outweighs current volatility.
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 32.732, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a positive long-term trend. Key support is at 10.2, with resistance at 12.02.
Revenue growth of 172% YoY in
Strong financial position with $441 million in cash.
Analysts maintain 'Buy' or 'Outperform' ratings, with price targets significantly above the current price.
OJEMDA product revenue projected to grow further in 2026.
Reduced net income and EPS in Q4
Short-term bearish technical indicators (negative MACD and RSI near oversold levels).
Analysts have lowered price targets recently, though they remain optimistic.
In Q4 2025, revenue increased by 83.92% YoY to $53.7 million, while net income dropped by 67.62% YoY to -$21.3 million. Gross margin slightly decreased to 88.68%. The company has a strong cash position of $441 million, supporting future growth.
Analysts maintain a positive outlook with 'Buy' and 'Outperform' ratings. Price targets range from $22 to $30, significantly higher than the current price of $10.435. Analysts are optimistic about OJEMDA's growth trajectory and clinical trial progress.
